110 likes | 325 Views
Microprosthetic Implant for the Treatment of Erectile Dysfunction. Matt Schwartz and Robert Douglas Advisor – Dr. Franz Baudenbacher. Thesis. A microprosthetic drug delivery implant has the potential to provide a biomimetic treatment option for erectile dysfunction. Minimally invasive
E N D
Microprosthetic Implant for the Treatment of Erectile Dysfunction Matt Schwartz and Robert Douglas Advisor – Dr. Franz Baudenbacher
Thesis • Amicroprosthetic drug delivery implant has the potential to provide a biomimetic treatment option for erectile dysfunction. • Minimally invasive • Patient compliance • Targeted drug release and control
Erectile Dysfunction Background • Erectile Dysfunction (ED) • Prevalence in men 40-70 = 52%1 • Current treatment options • Prescription oral pills • Injection therapy • Penile prosthetics • Drug therapy market size • $3.1 billion in 2005 • Estimated growth of 6.5% annually through 20102
Pathophysiology • Physiology of erection • Erectile tissue – cavernous smooth muscles • Low blood flow in flaccid state • Stimulation causes arterioles to dilate3 • Neurophysiologoy • Cavernous nerves – neurovascular control of erection/detumescence • Dorsal nerve – sensory function • Pathology of ED • Psychogenic • Neurogenic • Estimated at 10-19% • Iatrogenic • Arteriogenic • Combination
Problem and Solution • Current solutions • Oral prescription drugs • Injection therapy • Mechanical prosthetics • Proposed solution • Drug delivery implant • Triggered by neural signals of dorsal nerve • Microcontroller interprets signal • Microinjector drug release • Microcontroller regulates reactivation
Design Parameters • Dorsal nerve input interface • Drug reservoir, microprocessor, power supply, microinjector • Refillable reservoir • Power saving sleep mode • Candidates for drug release • Papaverine • Prostaglandin E1 • Affects reservoir size and flow specifications • Surgical Technique and Implantation • Site – Anterior face of pubic bone • Proximity to anatomical targets • Minimally invasive
Timeline of Future Work • Week ending 2/6/10 – Finalize list of components needed for proof of concept, consult with Dr. Doug Milam on device parameters • Week ending 2/13/10 – Order/fabricate proof of concept components • Week ending 2/20/10 – Contact pharmacologist and companies involved with related technologies • Week ending 2/27/10 – Assemble proof of concept device, change specifications with Dr. Doug Milam’s recommendations • Week ending 3/6/10 – Finalize specifications and component list for scaled up prototype device, order/fabricate components • Week ending 3/20/10 – Setup testing scenarios for prototype device • Week ending 3/27/10 – Begin assembly of prototype device • Week ending 4/3/10 – Complete prototype device assembly, begin device testing • Week ending 4/10/10 – Complete device testing, calculate specifications for to-scale device
References • Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. Urology 1994; 151: 54-61. • Elder, Melissa. Men’s Health: The Worldwide Market for Current and Emerging Drug Therapies, 2nd ed. Kalorma Information. May 2006. • Robert C. Dean, MD and Tom F. Lue, MD. Physiology of penile erection and pathophysiology of erectile dysfunction. UrolClin North Am. 2005 November; 32(4): 379-v. • “Codman 3000.” Codman Pumps. 15 Oct. 2009. Web. <http://www.codman.com/DePuy/products/Products/neuromodulation/pump/index.html>. • Sacral Plexus of the Right Side. Gray’s Anatomy.